What is Sermorelin?
Sermorelin (also known as GRF 1-29 NH2) is a growth hormone-releasing hormone (GHRH) analog consisting of the first 29 amino acids of the 44-amino acid human GHRH sequence. It represents the shortest fully functional fragment of GHRH.
As a GHRH analog, Sermorelin works by stimulating the pituitary gland to produce and release growth hormone through its natural pulsatile pattern. This mechanism preserves the body’s feedback systems, unlike direct GH administration.
Sermorelin was FDA-approved for diagnostic use and pediatric growth hormone deficiency, providing a foundation of clinical research data.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 5mg |
| Recommended BAC Water | 2.5mL |
| Resulting Concentration | 2mg/mL (2000mcg/mL) |
| Typical Research Dose | 200-500mcg |
| Frequency | 1-2x daily |
| Timing | Before bed and/or morning |
| Research Duration | 8-16 weeks |
Reconstitution Guide
Materials Needed
- Sermorelin 5mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare workspace — Clean area, gather materials, wash hands.
-
Clean vial stoppers — Wipe both vials with alcohol swabs. Allow to dry.
-
Draw BAC water — Draw 2.5mL bacteriostatic water using sterile syringe.
-
Add to peptide — Inject slowly down inside wall of vial. Do not spray directly on powder.
-
Dissolve — Sermorelin dissolves within 2-5 minutes. Gentle swirl if needed — never shake.
-
Verify — Solution should be clear and colorless.
-
Label and store — Write date on vial. Refrigerate immediately.
Dosage Protocol
Concentration Calculations
With 5mg peptide in 2.5mL BAC water:
- Concentration: 2mg/mL = 2000mcg/mL
- Per unit (U-100 syringe): 20mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 200mcg | 0.10mL | 10 units |
| 300mcg | 0.15mL | 15 units |
| 400mcg | 0.20mL | 20 units |
| 500mcg | 0.25mL | 25 units |
Suggested Research Protocol
Standard Protocol:
- Dose: 300mcg
- Frequency: Once daily before bed
- Duration: 12-16 weeks
Enhanced Protocol:
- Dose: 200-300mcg
- Frequency: 2x daily (morning + before bed)
- Duration: 12-16 weeks
Timing Considerations:
- Before bed: Aligns with natural GH secretion peak
- Morning (fasted): Secondary administration if using 2x daily
- Avoid: Within 2 hours of eating (food blunts response)
Injection Guide
Subcutaneous Administration
- Clean injection site with alcohol swab
- Pinch skin fold (abdomen preferred)
- Insert needle at 45-90° angle
- Inject slowly
- Wait 5 seconds before withdrawing
Optimal Timing
For best results in research:
- Inject at least 30-60 minutes before eating
- Evening dose: 30-60 minutes before sleep
- Morning dose: Upon waking, fasted state
Site Rotation
Rotate between:
- Abdomen (most common)
- Outer thigh
- Upper arm
Storage Requirements
Lyophilized (Powder Form)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Protect from light and moisture
Reconstituted
- Temperature: 2-8°C (36-46°F)
- Duration: 3-4 weeks
- Conditions: Protect from light, do not freeze
Research Considerations
Mechanism of Action
Sermorelin stimulates GH release through:
- GHRH receptor binding: Activates pituitary somatotrophs
- Pulsatile release: Maintains natural GH secretion patterns
- Feedback preservation: Does not override hypothalamic control
- IGF-1 increase: Secondary to GH elevation
Advantages Over Direct GH
| Sermorelin | Direct GH |
|---|---|
| Preserves pulsatile release | Continuous levels |
| Maintains feedback loops | Overrides feedback |
| Lower risk of supraphysiological levels | Dose-dependent elevation |
| More physiological | Pharmacological |
Synergistic Combinations
Research often combines Sermorelin with:
Ipamorelin (GHRP):
- GHRH + GHRP = synergistic GH release
- Common research combination
- Different receptor targets
CJC-1295:
- Extended half-life GHRH analog
- Can be used alternatively or in combination
Factors Affecting Response
Research has shown response may be influenced by:
- Age: Younger subjects typically show stronger response
- Body composition: Higher body fat may blunt response
- Sleep quality: GH release tied to sleep stages
- Fasting state: Fed state reduces GH response
- Blood glucose: Elevated glucose suppresses GH
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Vittone J, et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism. 1997;46:89-96.
- Walker RF. “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging. 2006;1:307-308.
- Merriam GR, et al. “Growth hormone-releasing hormone in aging.” Endocr Dev. 2013;25:65-87.
Last updated: December 01, 2025
Disclaimer: This information is for educational and research purposes only. Sermorelin is a research chemical not intended for human consumption. Always follow applicable laws and institutional guidelines.